Use of intravenous immunoglobulin in neurological disorders;Usage des immunoglobulines intraveineuses en neurologie

Revue Medicale Suisse

Volumn 1, Issue 17, 2005, Pages 1167-1170

  Steck, Andreas J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

BRAIN DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DYSGLOBULINEMIC NEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; INCLUSION BODY MYOSITIS; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PREVALENCE; REVIEW; PERIPHERAL NEUROPATHY;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33644800890     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Radziwill AJ, Kuntzer T, Steck AJ. Mécanismes immunitaires et traitements du syndrome de Guillain-Barré et des polyradiculoné vrites inflammatoires chroniques. Rev Neurol 2002;158:301-10.
2. Hartung HP, Toyka KV, Griffin JW. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. In: Antel J, Birnbaum G, Hartung HP eds, Clinical Neuroimmunology Oxford: Blackwell Sciences, 1998;294-306.
3. Plasma Exchange/Sandoglobuline Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-30.
4. Van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992;326:1123-9.
5. Latov N. Diagnosis of CIDP. Neurology 2002;59 (Suppl. 6): S2-S6.
6. Léger JM, Viala K. Acquisitions récentes dans le traitement des polyneuropathies dysimmunitaires chroniques. Rev Neurol;160:205-10.
7. Vermeulen M, Van der Meché FAG, Speelman JD, et al. Plasma and gamma-globuline infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317-26.
8. Van Doorn PA, Brand A, Strengers PFW, et al. High-dose intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy:A double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-12.
9. Van Doom PA, Vermeulen M, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1991;48:217-20.
10. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1076-7.
11. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon beta-1 a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999;53:1364-5.
12. Hadden RDM, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1 a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999;53:57-61.
13. Vallat JM, Hahn AF, Léger JM, et al. Interferon beta-1a as investigational treatment for CIDP. Neurology 2003;60(Suppl. 3):23-8.
14. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185:119-22.
15. Schweikert K, Radziwill AJ, Fuhr P, et al. Mycophenolate mofetil for chronic inflammatory and demyelinating polyradiculoneuropathy (CIDP): An open-labelled study. J Neurol 2003;251 (Suppl. 3):165.
16. Czaplinski A, Steck AJ. Immune mediated neuropathies: An update on therapeutic strategies. J Neurol 2004;251:127-37.
17. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GMI ganglioside. Ann Neurol 1988;24:73-8.
18. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18.
19. Pestronk A, Choksi R. Multifocal motor neuropathy: Serum IgM anti-GMI ganglioside antibodies in most patients detected using covalent linkage of GMI to ELISA plates. Neurology 1997;49:1289-92.
20. Claus D, Specht S, Zieschang M. Plasmapheresis in multifocal motor neuropathy:A case report J Neurol Neurosurg Psychiatry 2000;68:533-5.
21. Léger JM, Chassande B. Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double blind, placebo-controlled study. Brain 2001;124:145-53.
22. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GMI antibodies:A double-blind, placebo-controlled study. Neurology 1994;44:429-32.
23. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIG: A randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
24. Van den Berg-Vos RM, Franssen H, Visser J, et al. Disease severity in multifocal motor neuropathy and its association with the response to treatment. J Neurol 2002;3:330-6.
25. Taylor BV, Wright RA, Harper CM, et al. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-8.
26. Umapathi T, Hughes RAC, Nobile-Orazio E, et al. Immunosuppressive treatment for multifocal motor neuropathy (The Cochrane Library Issue 3) 2002.
27. Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710-7.
28. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-9.
29. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of anti-MAG associated polyneuropathy. Muscle Nerve 2003;27:611-5.
30. Gorson KC, Ropper AH, Weinberg DH, et al. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 2002;59:7766-72.
31. DiTroia A, Carpo A, Meucci N, et al. Clinical features and anti-neural activity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci 1999;164:64-71.
32. Magy L, Chassande B, Maisonobe T, et al. Polyneuropathy assocatied with IgG/IgA monoclonal gammopathy:A clinical and electrophysiological study of 15 cases. Eur J Neurol 2003;10:677-85.
33. Seybold ME. Plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1987;505:584-7.
34. Fornasari PM, Riva G, Piccolo G, et al. Short and long term clinical effects of plasma exchange in 33 cases of myasthenia gravis. J Artifical Organs 1985;8:159-62.
35. Antozzi G, Gemma M, Regi B, et al. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol 1991;238:103-7.
36. Gajdos Ph, Outin HD, Elkharrat D, et al. High-dose intravenous Gamma globulin for myasthenia gravis. Lancet 1984;:406-7.
37. Gajdos Ph, Chastang CI, Clair B, et al. First interim analysis of a randomised clinical trial comparing plasma exchange and intravenous immunoglobulin in myasthenia gravis. Neuromusc Disord 1994;4:551.
38. Gajdos Ph, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis (The Cochrane Library Issue 2) 2004.
39. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003;23:133-46.
40. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
41. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthy intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.
42. Strasser-Fuchs S, Fazekas F, Deisenhammer F, et al. The Austrian immunoglobulin in MS (AIMS) study: Final analysis. Mult Scler 2000;6:S9-S13.
43. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50:398-402.
44. Sorenson PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81.
45. Poehlau D, Federlein J, Postert T, et al. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins-interim results on drug safety of an ongoing study. IVIG study Group, Mult Scler 2000;6: S21-S3.
46. Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004;251:1133-7.
47. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIG: A double-blind, placebo-controlled study. Neurology 1997;48:712-6.
48. Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion-body myositis:A double-blind, placebo-controlled study. J Neurol 2000;247:22-8.